

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**国药集团**  
SINOPHARM

**CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED**  
**中國中藥控股有限公司**

*(Incorporated in Hong Kong with limited liability)*  
**(Stock Code: 570)**

**CONTINUING CONNECTED TRANSACTIONS**  
**DELAY IN DESPATCH OF CIRCULAR**

Reference is made to the announcement dated 11 November 2022 (the “**Announcement**”) of China Traditional Chinese Medicine Holdings Co. Limited (the “**Company**”, together with its subsidiaries as the “**Group**”) in relation to, among others, the renewal of continuing connected transactions in relation to the New Master Supply Agreement. Unless the context otherwise requires, capitalised terms in this announcement shall have the same meanings as defined in the Announcement.

As disclosed in the Announcement, a circular (the “**Circular**”) containing, among other things, (i) details of the New Master Supply Agreement and the transactions contemplated thereunder (including the Proposed Sales Caps); (ii) the letter of recommendation from the Independent Board Committee regarding the New Master Supply Agreement and the transactions contemplated thereunder (including the Proposed Sales Caps); (iii) the letter of advice from Gram Capital to the Independent Board Committee and the Independent Shareholders regarding the New Master Supply Agreement and the transactions contemplated thereunder (including the Proposed Sales Caps); and (iv) a notice of the EGM will be despatched to the Shareholders in compliance with the Listing Rules on or before 2 December 2022.

As additional time is required to finalise certain information to be included in the Circular, the despatch date of the Circular will be postponed to a date on or before 15 December 2022.

By order of the Board  
**China Traditional Chinese Medicine Holdings Co. Limited**  
**CHEN Yinglong**  
*Chairman*

Hong Kong, 2 December 2022

*As at the date of this announcement, the Board comprises twelve Directors, of which Mr. CHEN Yinglong, Mr. CHENG Xueren and Mr. YANG Wenming are executive Directors; Ms. LI Ru, Mr. YANG Binghua, Mr. WANG Kan, Mr. MENG Qingxin and Mr. KUI Kaipin are non-executive Directors; and Mr. XIE Rong, Mr. YU Tze Shan Hailson, Mr. QIN Ling and Mr. LI Weidong are independent non-executive Directors.*